n with SVR 12 / Total (%): Yes VS Reference | Univariate | Multivariate | |||
---|---|---|---|---|---|
OR (95% CI) | p-Value | OR (95% CI) | p-Value | ||
Ribavirin containing regimen (reference: no RBV) | 60/63 (95) VS 495/536 (92) | 1.66 (0.5–8.61) | 0.5936 | ||
Treatment duration 24 weeks (reference: 12 weeks) | 62/69 (90) VS 493/530 (93) | 0.67 (0.28–1.85) | 0.4654 | ||
Cirrhosis (reference: no cirrhosis) | 304/335 (91) VS 244/257 (95) | 0.52 (0.25–1.06) | 0.0734 | 1.07 (0.36–3.20) | 1.0000 |
Conjugated bilirubin ≥5 μmol/L (reference: < 5 μmol/L) | 163/182 (90) VS 141/148 (95) | 0.43 (0.15–1.1) | 0,0835 | 0.58 (0.19–1.67) | 0.3701 |
TP ≤ 70% (reference: > 70%) | 59/68 (87) VS 458/491 (93) | 0.47 (0.21–1.18) | 0.1103 | 0.41 (0.14–1.22) | 0.1148 |
Hemoglobin ≤12 g/dL for women or ≤ 13 g/dL for men(reference: > 12 g/dL or > 13 g/dL) | 63/72 (88) VS 480/514 (93) | 0.5 (0.22–1.23) | 0.1338 | 0.59 (0.22–1.71) | 0.3620 |
Platelets < 100,000/mm3 (reference: ≥ 100,000/mm3) | 108/121 (89) VS 429/458 (94) | 0.56 (0.27–1.22) | 0.1505 | 1.12 (0.39–3.38) | 1.0000 |
Genotype 1b (reference: 1 not subtyped or 1a or 4) | 280/297 (94) VS 275/302 (91) | 1.62 (0.83–3.24) | 0.1757 | 0.94 (0.39–2.26) | 1.0000 |
Male (reference: Female) | 303/322 (94) VS 252/277 (91) | 1.18 (0.65–2.13) | 0.6504 | 1.62 (0.68–3.94) | 0.3192 |
Genotype 1a (reference: 1 not subtyped or 1b or 4) | 127/141 (90) VS 428/458 (93) | 0.64 (0.32–1.34) | 0.2489 | ||
Neutrophil < 1500/mm3 (reference: ≥ 1500/mm3) | 33/38 (87) VS 503/540 (93) | 0.49 (0.17–1.69) | 0.2641 | ||
Chronic hepatitis duration ≥15 years (reference: < 15 years) | 308/337 (91) VS 236/251 (94) | 0.68 (0.33–1.34) | 0.2980 | ||
Albumin < 30 g/L (reference: ≥ 30 g/L) | 16/19 (84) VS 479/519 (92) | 0.45 (0.12–2.49) | 0.3756 | ||
Age > 65 years (reference: ≤ 65 years) | 209/223 (94) VS 346/376 (92) | 1.29 (0.65–2.7) | 0.5478 | ||
MELD ≥15 (reference: < 15) | 31/35 (89) VS 454/491 (92) | 0.63 (0.21–2.6) | 0.5732 | ||
Genotype 4 (reference: 1a or 1b or 1 not subtyped) | 121/132 (92) VS 434/467 (93) | 0.84 (0.4–1.89) | 0.7409 | ||
Viral load < 6 M at beginning of treatment (reference: ≥ 6 M) | 502/542 (93) VS 42/44 (95) | 0.6 (0.07–2.45) | 0.7425 | ||
ALAT > 5 ULN (reference: ≤ 5ULN) | 33/35 (94) VS 511/551 (93) | 1.29 (0.31–11.5) | 0.9999 | ||
ASAT > 5 ULN (reference: ≤ 5ULN) | 34/37 (92) VS 508/547 (93) | 0.87 (0.26–4.63) | 0.9999 | ||
Decompensated cirrhosis (reference: no decompensated cirrhosis) | 22/24 (92) VS 533/575 (93) | 0.87 (0.2–7.86) | 0.9999 | ||
Treatment experienced (reference: treatment naïve) | 160/173 (92) VS 395/426 (93) | 0.97 (0.48–2.07) | 0.9999 | ||
Genotype 1 not subtyped (reference: 1a or 1b or 4) | 27/29 (93) VS 528/570 (93) | 1.07 (0.25–9.63) | 0.9999 | ||
Previous treatment: PEG/RBV (reference: 1st generation PI/PEG/RBV or none) | 365/394 (93) VS 190/205 (93) | 0.99 (0.48–1.97) | 0.9999 |